Liquidia Corp (LQDA)
10.02
-0.24
(-2.39%)
USD |
NASDAQ |
Nov 14, 16:00
10.05
+0.02
(+0.25%)
Pre-Market: 20:00
Liquidia Research and Development Expense (Quarterly): 9.42M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 9.42M |
| March 31, 2024 | 10.06M |
| December 31, 2023 | 12.83M |
| September 30, 2023 | 7.44M |
| June 30, 2023 | 17.70M |
| March 31, 2023 | 5.278M |
| December 31, 2022 | 4.976M |
| September 30, 2022 | 4.512M |
| June 30, 2022 | 5.219M |
| March 31, 2022 | 4.728M |
| December 31, 2021 | 5.381M |
| September 30, 2021 | 4.487M |
| June 30, 2021 | 4.595M |
| March 31, 2021 | 6.054M |
| December 31, 2020 | 5.248M |
| Date | Value |
|---|---|
| September 30, 2020 | 7.661M |
| June 30, 2020 | 8.490M |
| March 31, 2020 | 10.82M |
| December 31, 2019 | 8.161M |
| September 30, 2019 | 10.94M |
| June 30, 2019 | 10.72M |
| March 31, 2019 | 10.66M |
| December 31, 2018 | 7.999M |
| September 30, 2018 | 7.157M |
| June 30, 2018 | 5.918M |
| March 31, 2018 | 7.627M |
| December 31, 2017 | 6.788M |
| September 30, 2017 | 6.533M |
| June 30, 2017 | 5.258M |
| March 31, 2017 | 6.176M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.487M
Minimum
Sep 2021
17.70M
Maximum
Jun 2023
7.529M
Average
6.054M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| United Therapeutics Corp | 103.50M |
| Arcturus Therapeutics Holdings Inc | 39.13M |
| Paragon 28 Inc | 7.083M |
| Tonix Pharmaceuticals Holding Corp | 9.698M |
| AIM ImmunoTech Inc | 1.145M |